Brind.
  1. Akebia Therapeutics is providing Vafseo for kidney disease treatment, which Innovative Renal Care has made available across all clinics.
  2. DaVita is starting an operational pilot for Vafseo, and Akebia expects IRC to operationalize the Vafseo protocols.

Akebia Therapeutics conducted a study within DaVita clinics on August 4, 2025.

1 report, 1 independent Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Akebia Therapeutics conducted a study within DaVita clinics on August 4, 2025.

Who's involved

What this event is mainly about
Akebia Therapeutics (United States)DaVita

Keep exploring

Part of

DaVita is starting an operational pilot for Vafseo, and Akebia expects IRC to operationalize the Vafseo protocols. All 1 developments

Within Akebia Therapeutics is providing Vafseo for kidney disease treatment, which Innovative Renal Care has made available across all clinics.

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAkebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics